PepGen (PEPG) Preferred Stock Liabilities (2021 - 2022)
PepGen (PEPG) reported Preferred Stock Liabilities of $112.1 million for Q1 2022, up 1359.41% on a YoY basis from $7.7 million in Q1 2021, and up 1225.8% sequentially from $8.5 million in Q4 2021.
PepGen (PEPG) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
PepGen (PEPG) has 2 years of Preferred Stock Liabilities data on file, last reported at $112.1 million in Q1 2022.
- For the quarter ending Q1 2022, Preferred Stock Liabilities rose 1359.41% year-over-year to $112.1 million; the trailing twelve-month figure through Mar 2022 stood at $112.1 million (up 1359.41% YoY), and the FY2021 full-year result was $8.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $112.1 million in Q1 2022, from $8.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $112.1 million in Q1 2022 to a low of $7.7 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | PepGen | 145.09 Mn | 145.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 112.08 Mn |
| Dec 31, 2021 | 8.45 Mn |
| Sep 30, 2021 | 44.64 Mn |
| Jun 30, 2021 | 8.45 Mn |
| Mar 31, 2021 | 7.68 Mn |